BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 18094073)

  • 1. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
    Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
    Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
    Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Eszterhas A; Hunter DS; Glassberg MK; Yeung RS; Walker CL; Noonan D; Kwiatkowski DJ; Chou MM; Panettieri RA; Krymskaya VP
    J Biol Chem; 2002 Aug; 277(34):30958-67. PubMed ID: 12045200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
    Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
    Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC2 modulates cell adhesion and migration via integrin-α1β1.
    Moir LM; Black JL; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
    Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
    Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
    Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposition to tetraploidy in pulmonary vascular smooth muscle cells derived from the Eker rats.
    Gui Y; He GH; Walsh MP; Zheng XL
    Am J Physiol Lung Cell Mol Physiol; 2007 Sep; 293(3):L702-11. PubMed ID: 17575014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.